Teon Therapeutics is a pharmaceutical company developing a pipeline of novel small molecules to address unmet needs in oncology. Teon is focused on GPCR (G protein-coupled receptor) targets and has assembled a team of top GPCR biologists and chemists to develop its pipeline. GPCRs are a proven drug target, accounting for >30% of all FDA approved drugs, and have emerged as a high potential target in oncology, particularly adenosine pathways in the tumor microenvironment.